Sabby Management’s Biodexa Pharmaceuticals BDRX Stock Holding History

Sabby Management’s Portfolio BDRX Stock Details BDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,437	Closed	-$159K	–	25
2026 Q1	$159K	Buy	6,437 +1,671	+35%	+$94.1K	0.35%	16
2025 Q4	$433K	Buy	+4,766	New	+$1.08M	0.62%	15

Other funds holding BDRX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

APW

Allied Private Wealth Boca Raton, Florida $156M AUM

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Hilton Head Capital Partners Hilton Head Island, South Carolina $185M AUM 26.97% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Sabby Management's BDRX Position: Q2 2026 in Review

Sabby Management sold out of Biodexa Pharmaceuticals (BDRX) in Q2 2026, closing a stake of 6,437 shares — an estimated $159K sold.

Sabby Management first reported a position in BDRX in Q4 2025 and held it in 2 quarters. The position peaked at $433K in Q4 2025. 7 funds tracked by Wall St. Rank hold BDRX as of Q2 2026.

Sabby Management reported no remaining Biodexa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sabby Management sold 6,437 Biodexa Pharmaceuticals shares in Q2 2026, an estimated $159K.
Sabby Management first reported a position in Biodexa Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Sabby Management's Biodexa Pharmaceuticals position peaked at $433K in Q4 2025.
7 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.